Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Spironolactone use linked to lower prostate cancer risk

Publish date:: March 17, 2020

Key clinical point: Prostate cancer (PCa) risk is lower among men exposed to the diuretic spironolactone.

Major finding: Men who were prescribed spironolactone had a lower risk for PCa (adjusted odds ratio [OR], 0.83). Reduction in PCa risk was greater among current users (OR, 0.77) than past users (OR, 0.88), and a significant trend toward a decreased risk was observed with increasing dose intensity (P_trend less than .001).

Study details: A case-control study of 31,591 men with PCa and 156,802 matched controls using data from the Prostate Cancer Data Base Sweden (PCBaSe).

Disclosures: PCBaSe was supported by The Swedish Research Council (2017-00847) and The Swedish Cancer Society. Kerri Beckmann was funded through a NHMRC Early Career Research Fellowship. The authors declared no conflicts of interest.

Citation:

Beckmann K et al. Prostate Cancer Prostatic Dis. 2020 Mar 2. doi: 10.1038/s41391-020-0220-8.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,